Losoxantrone

Drug Profile

Losoxantrone

Alternative Names: Biantrazole; CI 941; DUP 941; NSC 357885; PD 113785

Latest Information Update: 16 Jan 2008

Price : $50

At a glance

  • Originator Pfizer
  • Developer Bristol-Myers Squibb; Pfizer
  • Class Anthraquinones; Antineoplastics; Pyrazolones; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 21 Jun 2000 Warner-Lambert has merged with Pfizer
  • 29 Apr 1999 A clinical study has been added to the pharmacokinetics and adverse events sections
  • 19 Oct 1998 Phase-II clinical trials for Prostate cancer in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top